Premier Graphene (BIEI) 10-Q 21 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Nov. 13, 2017
Document And Entity Information
Entity Registrant Name	PREMIER BIOMEDICAL INC
Entity Central Index Key	1,515,740
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer	No
Is Entity a Voluntary Filer	No
Is Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		531,188,624
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,017

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash	$ 102,517	$ 22,437
Accounts receivable	834
Inventory	108,006
Prepaid expenses	7,435	11,430
Total current assets	218,792	33,867
Property and equipment, net	5,940	5,100
Total assets	224,732	38,967
Current liabilities:
Accounts Payable	350,077	220,740
Accounts payable, related parties	52,244	52,489
Accrued interest	1,743	18,026
Accrued interest, related parties	5,370	3,570
Convertible notes payable, net of discounts of $80,850 and $149,456 'at September 30, 2017 and December 31, 2016, respectively	69,150	153,024
Notes payable, related parties	30,000	30,000
Derivative liabilities	2,376,295	221,822
Total current liabilities	2,884,879	699,671
Total liabilities	2,884,879	699,671
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, $0.001 par value, 10,000,000 shares 'authorized, 2,000,000 and -0- shares issued and outstanding 'at September 30, 2017 and December 31, 2016, respectively	2,000	2,000
Common stock, $0.00001 par value, 1,000,000,000 shares 'authorized, 491,852,004 and 304,556,650 shares issued and 'outstanding at September 30, 2017 and December 31, 2016, respectively	4,919	3,046
Additional paid in capital	12,753,194	11,899,504
Accumulated deficit	(15,420,260)	(12,565,254)
Total stockholders' equity (deficit)	(2,660,147)	(660,704)
Total liabilities and stockholders' equity (deficit)	$ 224,732	$ 38,967

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current liabilities:
Convertible notes payable, net of discounts	$ 80,850	$ 149,456
Stockholders' equity (deficit):
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized shares	10,000,000	10,000,000
Preferred stock, issued shares	2,000,000	0
Preferred stock, outstanding shares	2,000,000	0
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, authorized shares	1,000,000,000	1,000,000,000
Common stock, issued shares	491,852,004	304,556,650
Common stock, outstanding shares	491,852,004	304,556,650

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue	$ 24,276		$ 24,276
Cost of goods sold	11,070		11,070
Gross Profit	13,206		13,206
Operating expenses:
Research and development	184,315		184,315
General and administrative	36,979		110,284
Professional fees	22,269		109,025
Total operating expenses	243,563		403,624
Net operating loss	(230,357)		(390,418)
Other income (expense):
Interest expense	(37,124)		(190,471)
Other expense
Change in derivative liabilities	3,993,216		(2,267,885)	$ (24,434)
Loss on joint venture	(4,174)		(6,232)
Total other income (expenses)	3,951,918		(2,464,588)
Net loss	$ 3,721,561		$ (2,855,006)
Weighted average number of common shares outstanding - basic and fully diluted	504,697,855		469,764,275
Net loss per share - basic and fully diluted	$ 0.01		$ (0.01)
Restated [Member]
Revenue
Cost of goods sold
Gross Profit
Operating expenses:
Research and development		46,056		105,742
General and administrative		36,566		128,032
Professional fees		68,537		294,496
Total operating expenses		151,159		528,270
Net operating loss		(151,159)		(528,270)
Other income (expense):
Interest expense		(282,434)		(691,245)
Other expense				(340,647)
Change in derivative liabilities		63,428		(24,434)
Loss on joint venture
Total other income (expenses)		(219,006)		(1,056,326)
Net loss		$ (370,165)		$ (1,584,596)
Weighted average number of common shares outstanding - basic and fully diluted		165,387,269		122,769,016
Net loss per share - basic and fully diluted		$ 0		$ (0.01)

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (2,855,006)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,854
Change in fair market value of derivative liabilities	2,267,885	$ 24,434
Amortization of debt discount	184,237
Stock based compensation, related parties
Stock based compensation
Decrease (increase) in assets:
Accounts receivable	(834)
Inventory	(108,006)
Prepaid expenses	3,995
Increase (decrease) in liabilities:
Accounts payable	129,337
Accounts payable, related parties	(245)
Accrued interest	4,434
Accrued interest, related parties	1,800	1,200
Judgment payable
Net cash used in operating activities	(370,549)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(2,694)
Net cash used in investing activities	(2,694)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of stock, net of offering costs	285,000
Proceeds from sale of stock on equity line of credit	18,323
Proceeds from exercise of warrants, related party
Proceeds of convertible notes payable	150,000
Repayments of convertible notes payable
Net cash provided by financing activities	453,323
NET CHANGE IN CASH	80,080
CASH AT BEGINNING OF PERIOD	22,437
CASH AT END OF PERIOD	102,517
SUPPLEMENTAL INFORMATION:
Interest paid
Income taxes paid
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Value of debt discounts	115,631
Value of derivative adjustment due to debt conversions	229,043
Value of shares issued for conversion of debt	323,197
Common stock issued for settlement of accounts payable, related party
Cashless exercise of common stock warrants, 2,250,000 warrants exercised
Restated [Member]
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		(1,584,596)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		1,554
Change in fair market value of derivative liabilities		24,434
Amortization of debt discount		633,145
Stock based compensation, related parties		19,595
Stock based compensation		74,832
Decrease (increase) in assets:
Accounts receivable
Inventory
Prepaid expenses		(3,879)
Increase (decrease) in liabilities:
Accounts payable		21,790
Accounts payable, related parties		11,341
Accrued interest		56,299
Accrued interest, related parties		1,800
Judgment payable		340,647
Net cash used in operating activities		(403,038)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment		(3,536)
Net cash used in investing activities		(3,536)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of stock, net of offering costs
Proceeds from sale of stock on equity line of credit		68,520
Proceeds from exercise of warrants, related party		2,000
Proceeds of convertible notes payable		417,500
Repayments of convertible notes payable		(89,039)
Net cash provided by financing activities		398,981
NET CHANGE IN CASH		(7,593)
CASH AT BEGINNING OF PERIOD		35,414
CASH AT END OF PERIOD		27,821
SUPPLEMENTAL INFORMATION:
Interest paid		13,539
Income taxes paid
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Value of debt discounts
Value of derivative adjustment due to debt conversions		369,924
Value of shares issued for conversion of debt		488,552
Common stock issued for settlement of accounts payable, related party		13,765
Cashless exercise of common stock warrants, 2,250,000 warrants exercised		$ 22

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Note 1 - Basis of Presentation and Significant Accounting Policies	Basis of Presentation The accompanying unaudited, condensed financial statements of Premier Biomedical, Inc. (“the Company”) have been prepared pursuant to rules and regulations of the Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, these statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. It is suggested that these statements be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016. Equity Method Investee companies that are not consolidated, but over which the Company exercises significant influence, are accounted for under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an Investee depends on an evaluation of several factors including, among others, representation on the Investee company’s board of directors and ownership level, which is generally a 20% to 50% interest in the voting securities of the Investee company. Under the equity method of accounting, an Investee company’s accounts are not reflected within the Company’s Balance Sheets and Statements of Operations; however, the Company’s share of the earnings or losses of the Investee company is reflected in the caption “Equity in losses of unconsolidated entity” in the Statements of Operations. The Company’s carrying value in an equity method Investee company is typically reflected in the caption “Investment in Joint Venture.” in the Company’s Balance Sheets. As of September 30, 2017, our share of losses from the investee company exceeded our basis, therefore the investment is not currently presented on the balance sheet. U.S. GAAP considers a change in reporting entity to include “changing specific subsidiaries that make up the group of entities for which consolidated financial statements are presented.” Circumstances may arise where a parent’s controlling financial interest (e.g., generally an ownership interest in excess of 50 percent of the outstanding voting stock) is reduced to a noncontrolling investment that still enables it to exercise significant influence over the operating and financial policies of the investee. A change that results from changed facts and circumstances (such as a partial sale of a subsidiary), where there was only one acceptable method of accounting prior to the change in circumstances (consolidation) and only one acceptable method of accounting after the change (equity method accounting), is not a change in reporting entity and is not be accounted for retrospectively. Accordingly, a change from a controlling interest to a noncontrolling investment accounted for under the equity method is accounted for prospectively from the date of change in control. When the Company’s carrying value in an equity method Investee company is reduced to zero, no further losses are recorded in the Company’s consolidated financial statements unless the Company guaranteed obligations of the Investee company or has committed additional funding. When the Investee company subsequently reports income, the Company will not record its share of such income until it equals the amount of its share of losses not previously recognized. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents We maintain cash balances in non-interest-bearing accounts, which do not currently exceed federally insured limits. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. Patent Rights and Applications Patent rights and applications costs include the acquisition costs and costs incurred for the filing of patents. Patent rights and applications are amortized on a straight-line basis over the legal life of the patent rights beginning at the time the patents are approved. Patent costs for unsuccessful patent applications are expensed when the application is terminated. Fair Value of Financial Instruments Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, prepaid expenses and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short term nature of the instruments. Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share. Stock-Based Compensation Under FASB ASC 718-10-30-2, all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative. The Company’s stock based compensation consisted of the following during the nine months ended September 30, 2017 and 2016, respectively: September 30, September 30, 2017 2016 Common stock issued for services $ - $ 58,800 Warrants issued for services, related parties - 19,595 Warrants issued for services - 16,032 Total stock based compensation $ - $ 94,427 Revenue Recognition Sales on fixed price contracts are recorded when services are earned, the earnings process is complete or substantially complete, and the revenue is measurable and collectability is reasonably assured. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue from sales in which payment has been received, but the earnings process has not occurred. Sales commenced on July 5, 2017 with the termination of our joint venture and are recognized upon shipment of goods, which are typically paid for at the time of order. Advertising and Promotion All costs associated with advertising and promoting products are expensed as incurred. These expenses were $42,793 and $67,216 for the nine months ended September 30, 2017 and 2016, respectively. Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations. Uncertain Tax Positions In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions. Recent Accounting Pronouncements In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2017-09 , Compensation — Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-9 In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other (Topic 350) In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business No other new accounting pronouncements, issued or effective during the nine months ended September 30, 2017, have had or are expected to have a significant impact on the Company’s financial statements.

Going Concern

Going Concern	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Note 2 - Going Concern	As shown in the accompanying financial statements, the Company has no revenues, incurred net losses from operations resulting in an accumulated deficit of $15,420,260, and had negative working capital of ($2,666,087) at September 30, 2017. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company is currently seeking additional sources of capital to fund short term operations. The Company, however, is dependent upon its ability to secure equity and/or debt financing and there are no assurances that the Company will be successful; therefore, without sufficient financing it would be unlikely for the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. The financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Restatement

Restatement	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Note 3 - Restatement	The Company is restated its December 31, 2015 financial statements and is restating the interim financial statements for the three months ended March 31, 2016, the six months ended June 30, 2016 and nine months ended September 30, 2016 in order to account for embedded derivatives within the Redwood Notes, rather than beneficial conversion feature discounts. The financial statements will be restated prospectively during 2017. The Company determined that it had not properly recognized embedded derivative liabilities within the Redwood Notes that originated on various dates between December 28, 2015 and May 27, 2016. The Company has recognized a derivative liability in lieu of the previously recognized beneficial conversion feature and the related change in derivative liabilities and amortization of the debt discount expenses have been adjusted to correct this error. The following adjustments were made to the September 30, 2016 Restated Balance Sheet: PREMIER BIOMEDICAL, INC. BALANCE SHEET As Originally Reported As Restated September 30, September 30, 2016 Adjustments 2016 ASSETS Current assets: Cash $ 27,821 $ - $ 27,821 Prepaid expenses 13,045 - 13,045 Total current assets 50,133 - 50,133 Property and equipment, net 5,629 - 5,629 Total assets $ 46,495 $ - $ 46,495 LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Current liabilities: Accounts payable $ 210,055 $ - $ 210,055 Accounts payable, related parties 52,244 - 52,244 Accrued interest 43,330 - 43,330 Accrued interest, related parties 2,970 - 2,970 Judgment payable 340,647 - 340,647 Convertible notes payable, net of discounts of $74,287 184,470 (28,837 ) 155,633 Notes payable, related parties 30,000 - 30,000 Derivative liabilities - 184,583 184,583 Total current liabilities 863,716 155,746 1,019,462 Total liabilities 863,716 155,746 1,019,462 Commitments and contingencies - - - Stockholders’ equity (deficit): Preferred stock, $0.001 par value, 10,000,000 shares authorized, 2,000,000 shares issued and outstanding 2,000 - 2,000 Common stock, $0.00001 par value, 1,000,000,000 shares authorized, 185,858,819 shares issued and outstanding 1,859 - 1,859 Additional paid in capital 11,529,099 (124,296 ) 11,404,803 Accumulated deficit (12,350,179 ) (31,450 ) (12,381,629 ) Total stockholders’ equity (deficit) (817,221 ) (155,746 ) (972,967 ) Total liabilities and stockholders’ equity (deficit) $ 46,495 $ - $ 46,495 The following adjustments were made to the Nine Months Ended September 30, 2016 Restated Statement of Operations: PREMIER BIOMEDICAL, INC. STATEMENT OF OPERATIONS As Originally Reported As Restated September 30, September 30, 2016 Adjustments 2016 Revenue $ - $ - $ - Operating expenses: Research and development 105,742 - 105,742 General and administrative 128,032 - 128,032 Professional fees 294,496 - 294,496 Total operating expenses 528,270 - 528,270 Net operating loss (528,270 ) - (528,270 ) Other expense: Interest expense (703,465 ) 12,220 (691,245 ) Other expense (340,647 ) - (340,647 ) Change in derivative liabilities - (24,434 ) (24,434 ) Total other expenses (1,044,112 ) (12,214 ) (1,056,326 ) Net loss $ (1,572,382 ) $ (12,214 ) $ (1,584,596 ) The following adjustments were made to the Three Months Ended September 30, 2016 Restated Statement of Operations: PREMIER BIOMEDICAL, INC. STATEMENT OF OPERATIONS As Originally Reported As Restated September 30, September 30, 2016 Adjustments 2016 Revenue $ - $ - $ - Operating expenses: Research and development 46,056 - 46,056 General and administrative 36,566 - 36,566 Professional fees 68,537 - 68,537 Total operating expenses 151,159 - 151,159 Net operating loss (151,159 ) - (151,159 ) Other expense: Interest expense (283,988 ) 1,554 (282,434 ) Change in derivative liabilities - 63,428 - Total other expenses (283,988 ) 64,982 (219,006 ) Net loss $ (435,147 ) $ 64,982 $ (370,165 ) The following adjustments were made to the September 30, 2016 Restated Statement of Cash Flows: PREMIER BIOMEDICAL, INC. STATEMENT OF CASH FLOWS As Originally Reported As Restated September 30, September 30, 2016 Adjustments 2016 CASH FLOWS FROM OPERATING ACTIVITIES Net loss $ (1,572,382 ) $ (12,214 ) $ (1,584,596 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation 1,554 - 1,554 Change in fair market value of derivative liabilities - 24,434 24,434 Amortization of debt discounts 645,365 (12,220 ) 633,145 Stock based compensation, related parties 19,595 - 19,595 Stock based compensation 74,832 - 74,832 Decrease (increase) in assets: Prepaid expenses (3,879 ) - (3,879 ) Increase (decrease) in liabilities: Accounts payable 21,790 - 21,790 Accounts payable, related parties 11,341 - 11,341 Accrued interest 56,299 - 56,299 Accrued interest, related parties 1,800 - 1,800 Judgment payable 340,647 - 340,647 Net cash used in operating activities (403,038 ) - (403,038 ) CASH FLOWS FROM INVESTING ACTIVITIES Purchases of property and equipment (3,536 ) - (3,536 ) Net cash used in investing activities (3,536 ) - (3,536 ) CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from exercise of warrants, related party 2,000 - 2,000 Proceeds from sale of stock on equity line of credit 68,520 - 68,520 Proceeds from convertible notes payable 417,500 - 417,500 Repayments from convertible notes payable (89,039 ) - (89,039 ) Net cash provided by financing activities 398,981 - 398,981 NET CHANGE IN CASH (7,593 ) - (7,593 ) CASH AT BEGINNING OF PERIOD 35,414 - 35,414 CASH AT END OF PERIOD $ 27,821 $ - $ 27,821 SUPPLEMENTAL INFORMATION: Interest paid $ 13,539 $ - $ 13,539 Income taxes paid $ - $ - $ - NON-CASH INVESTING AND FINANCING ACTIVITIES: Discount on beneficial conversion feature on convertible note $ 364,220 $ (364,220 ) $ - Value of debt discounts $ - $ 369,924 $ 369,924 Value of shares issued for conversion of debt $ 488,552 $ - $ 488,552 Cashless exercise of common stock warrants $ 22 $ - $ 22 Common stock issued for settlement of accounts payable $ 13,765 $ - $ 13,765

Related Parties

Related Parties	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Note 4 - Related Parties	Other Receivable The Company advanced a total of $48,778 to its joint venture partner, Premier Biomedical Pain Management Solutions, LLC, and was subsequently repaid a total of $44,604 on July 5, 2017 with the termination of the joint venture, resulting in a loss of $6,232, consisting of the original investment of $2,058 and the loss on this receivable of $4,174. Accounts Payable The Company owed $46,016 and $46,016 as of September 30, 2017 and December 31, 2016, respectively, to entities owned by the Chairman of the Board of Directors. The amounts are related to patent costs and reimbursable expenses paid by the Chairman on behalf of the Company. The Company owed $605 and $306 as of September 30, 2017 and December 31, 2016, respectively, to the Company’s CEO for reimbursable expenses. The Company owed $5,623 and $6,167 as of September 30, 2017 and December 31, 2016, respectively, amongst members of the Company’s Board of Directors for reimbursable expenses. Notes Payable On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from the Company’s CEO. On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from the Company’s Chairman of the Board. On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from one of the Company’s Directors. Accrued interest of $5,370 was outstanding on these notes as of September 30, 2017.

Patent Rights and Applications

Patent Rights and Applications	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Note 5 - Patent Rights and Applications	The Company amortizes its patent rights and applications on a straight line basis over the expected useful technological or economic life of the patents, which is typically 17 years from the legal approval of the patent applications when there is probable future economic benefits associated with the patent. The Company has elected to expense all of their patent rights and application costs due to difficulties associated with having to prove the value of their future economic benefits. All patent applications are currently pending and the Company has no patents that have yet been approved. It is the Company’s policy that it performs reviews of the carrying value of its patent rights and applications on an annual basis. On March 4, 2015, we entered into a Patent License Agreement (“PLA”) with the University of Texas at El Paso (“UTEP”) regarding our joint research and development of CTLA-4 Blockade with Metronomic Chemotherapy for the Treatment of Breast Cancer. This is the first PLA with UTEP following our Collaborative Agreement with them dated May 9, 2012, and memorializes the joint ownership of the applicable patent and the financial and other terms related thereto. On June 19, 2015, we entered into Amendment No. 1 to this Agreement, pursuant to which we explicitly included Provisional Patent Application No. 62/161,116 entitled, “Anti-CTLA-4 Blockade” (the “Application”) under the definition of “Patent Rights” as set forth in the PLA. The Application was filed with the United States Patent and Trademarks Office on May 13, 2015; the underlying technology was invented by Robert Kirken and Georgialina Rodriguez, and is solely-owned by The Board of Regents of The University of Texas System.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Note 6 - Fair Value of Financial Instruments	Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value. The Company has certain financial instruments that must be measured under the new fair value standard. The Company’s financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of September 30, 2017 and December 31, 2016, respectively: Fair Value Measurements at September 30, 2017 Level 1 Level 2 Level 3 Assets Cash $ 102,517 $ - $ - Total assets 102,517 - - Liabilities Convertible notes payable 69,150 Notes payable, related parties - 30,000 - Derivative liabilities - - 2,376,295 Total liabilities - 99,150 2,376,295 $ 102,517 $ (99,150 ) $ (2,376,295 ) Fair Value Measurements at December 31, 2016 Level 1 Level 2 Level 3 Assets Cash $ 22,437 $ - $ - Total assets 22,437 - - Liabilities Convertible note payable, net of discounts - 153,024 - Notes payable, related parties 30,000 - Derivative liabilities - - 221,822 Total liabilities - 183,024 221,822 $ 22,437 $ (183,024 ) $ (221,822 ) The fair values of our related party debts are deemed to approximate book value, and are considered Level 2 inputs as defined by ASC Topic 820-10-35. There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the nine months ended September 30, 2017 or the year ended December 31, 2016.

Joint Venture

Joint Venture	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Note 7 - Joint Venture	On September 13, 2016, we entered into an operating agreement to form a pain management joint venture company with Advanced Technologies Solutions (ATS), a company based in San Diego, California and owned by Ronald T. LaBorde, a member of our Board of Directors. The joint venture company, Premier Biomedical Pain Management Solutions, LLC, a Nevada limited liability company (PBPMS), to develop and market natural and cannabis-based generalized, neuropathic, and localized pain relief treatment products. We owned 50% of PBPMS and ATS owned the other 50%, with 89% of the profits allocated to us and the remaining 11% of profits allocated to ATS. As part of the agreement with ATS, Mr. LaBorde was appointed a member of our Board of Directors. PBPMS was required to enter into separate license agreements with us and ATS for the use of technology previously developed by both companies. Intellectual property developed jointly by the parties will be the property of PBPMS. However, ATS and Mr. LaBorde could have developed inventions and intellectual property independently from PBPMS, and such inventions and intellectual property would have been the sole property of ATS or Mr. LaBorde. Pursuant to the terms of the PBPMS operating agreement, The Company was to tender 1,250,000 warrants, for the purchase of an equal number of shares of our common stock at a strike price of $0.05, pursuant to the license agreement between ATS and PBPMS. The Company and Mr. LaBorde did not execute the license agreement or issue these warrants, and on July 5, 2017, the Company terminated the joint venture agreement, resulting in a loss of $6,232. Our initial capital contribution to PBPMS was $25,000. ATS was to contribute (i) technical, labor, manufacturing information and know-how required to produce the initial product, an extended duration topical pain relief patch; (ii) $5,000 worth of primary ingredients; and (iii) $5,000 worth of other materials to produce the initial prototype pain relief patches. PBPMS was managed by a board of managers (PBPMS Board). The PBPMS Board consisted of William A. Hartman, our President and Chief Executive Officer and member of our Board of Directors, Ronald T. LaBorde, the Founder of ATS and member of our Board of Directors, Dr. Patricio Reyes, our Chief Technology Officer and member of our Board of Directors, and John Borza, our Vice-President and member of our Board of Directors. Decisions of the PBPMS Board require unanimous approval. The PBPMS operating agreement was subject to other common terms and ownership transfer restrictions, including a right of first refusal; however, the operating agreement and entity were dissolved upon the termination of the joint venture on July 5, 2017.

Subsidiary Formation

Subsidiary Formation	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Note 8 - Subsidiary Formation	On September 14, 2017, we formed Premier Biomedical Pain Relief Meds, LLC as a wholly-owned subsidiary. No activity has been conducted within this entity as of the date of this filing.

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Note 9 - Convertible Notes Payable	Convertible notes payable consist of the following at September 30, 2017 and December 31, 2016, respectively: September 30, December 31, 2017 2016 On August 8, 2017, the Company entered into an exchange agreement with Diamond Rock, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First Diamond Rock Note”)issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. $ 50,000 $ - On August 8, 2017, the Company entered into an exchange agreement with The Special Equities Group, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First SEG Note”)issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. 50,000 - On August 8, 2017, the Company entered into an exchange agreement with RDW Capital, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First RDW Note”)issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. 50,000 - On October 10, 2016, the Company issued a 10% interest bearing; unsecured convertible promissory note with a face value of $300,000 (“Seventh Redwood Note”), which matures on October 10, 2017, pursuant to a Warrant Purchase Agreement by and among Redwood Management, LLC, the Company and Typenex. Pursuant to this agreement, Redwood purchased the warrants from Typenex, and Typenex provided a Satisfaction of Judgment and Release of Garnishment to release the Writ of Garnishment Typenex had placed on our transfer agent. Redwood paid installment payments to Typenex in the aggregate amount of $300,000, which were completed on, or about November 10, 2016. The principal and interest of the Seventh Redwood Note is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law. This settled the dispute with Typenex. A total of $308,750, consisting of $300,000 of principal and $8,750 of interest, was converted into 135,596,882 shares of common stock on various dates between November 21, 2016 and February 24, 2017. $ - $ 275,000 On March 11, 2016, the Company received net proceeds of $90,000 in exchange for a 10% interest bearing; unsecured convertible promissory note with a face value of $105,000 (“Fifth Redwood Note”), which matures on December 11, 2016. The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law. A total of $120,517, consisting of $105,000 of principal and $15,517 of interest, was converted into an aggregate of 47,820,025 shares of common stock at various dates between November 8, 2016 and March 13, 2017. - 27,480 Total convertible notes payable 150,000 302,480 Less unamortized derivative discounts: 80,850 149,456 Convertible notes payable 69,150 153,024 Less: current portion 69,150 153,024 Convertible notes payable, less current portion $ - $ - The Company recognized interest expense for the nine months ended September 30, 2017 and 2016, respectively, as follows: September 30, September 30, 2017 2016 Interest on convertible notes $ 4,434 $ 35,048 Interest on related party loans 1,800 1,200 Amortization of beneficial conversion feature - 81,648 Amortization of OID - 20,647 Amortization of loan origination costs - 44,811 Derivative discounts 184,237 225,457 Total interest expense $ 190,471 $ 408,811

Notes Payable, Related Parties

Notes Payable, Related Parties	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Note 10 - Notes Payable, Related Parties	Notes payable, related parties consist of the following at September 30, 2017 and December 31, 2016, respectively: September 30, December 31, 2017 2016 On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from the Company’s CEO. $ 10,000 $ 10,000 On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from the Company’s Chairman of the Board. 10,000 10,000 On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from one of the Company’s Directors. 10,000 10,000 Total notes payable, related parties 30,000 30,000 Less: current portion 30,000 30,000 Notes payable, related parties, less current portion $ - $ - The Company recorded interest expense in the amount of $1,800 and $1,800 for the nine months ended September 30, 2017 and 2016, respectively related to notes payable, related parties.

Derivative Liabilities

Derivative Liabilities	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Note 11 - Derivative Liabilities	As discussed in Note 9 under Convertible Notes Payable, the Company issued debts that consist of the issuance of convertible notes with variable conversion provisions. The conversion terms of the convertible notes are variable based on certain factors, such as the future price of the Company’s common stock. The number of shares of common stock to be issued is based on the future price of the Company’s common stock. The number of shares of common stock issuable upon conversion of the promissory note is indeterminate. Due to the fact that the number of shares of common stock issuable could exceed the Company’s authorized share limit, the equity environment is tainted and all additional convertible debentures and warrants are included in the value of the derivative. Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the variable conversion option and warrants and shares to be issued were recorded as derivative liabilities on the issuance date. The fair values of the Company’s derivative liabilities were estimated at the issuance date and are revalued at each subsequent reporting date, using a lattice model. The Company recognized current derivative liabilities of $2,376,295 and $221,822 at September 30, 2017 and December 31, 2016, respectively. The change in fair value of the derivative liabilities resulted in a loss of $2,267,885 and $24,434 for the nine months ended September 30, 2017 and 2016, respectively, which has been reported within other expense in the statements of operations. The loss of $2,267,885 for the nine months ended September 30, 2017 consisted of a loss of $3,337,007 due to the value attributable to the warrants, a gain of $1,052,505 in market value of the warrants and a net gain in market value of $16,617 on the convertible notes. The loss of $24,434 for the nine months ended September 30, 2016 consisted of a loss of $125,763 due to the value in excess of the face value of the convertible notes and a net gain in market value of $101,329 on the convertible notes. The following is a summary of changes in the fair market value of the derivative liability during the nine months ended September 30, 2017 and the year ended December 31, 2016, respectively: Derivative Liability Total Balance, December 31, 2015 $ 150,076 Increase in derivative value due to issuances of convertible promissory notes 583,415 Change in fair market value of derivative liabilities due to the mark to market adjustment 13,816 Debt conversions (525,485 ) Balance, December 31, 2016 $ 221,822 Increase in derivative value due to issuances of convertible promissory notes 115,631 Increase in derivative value due to issuances of warrants 3,337,007 Change in fair market value of derivative liabilities due to the mark to market adjustment (1,069,122 ) Debt conversions (229,043 ) Balance, September 30, 2017 $ 2,376,295 Key inputs and assumptions used to value the convertible debentures and warrants issued during the nine months ended September 30, 2017: · Stock price ranging from $0.009 to $0.0081 during these periods would fluctuate with projected volatility. · The notes convert with variable conversion prices and fixed conversion prices (tainted notes). · An event of default would occur -0-% of the time, increasing 2% per month to a maximum of 20%. · The projected annual volatility curve for each valuation period was based on the historical annual volatility of the company in the range of 199% - 187%. · The Company would redeem the notes -0-% of the time, increasing 1% per month to a maximum of 5%. · All notes are assumed to be extended at maturity by 2 years – the time required to convert out this volume of stock. · The holders of the securities would automatically convert midway through to maturity on a monthly basis based on ownership and trading volume limitations. · A change of control and fundamental transaction would occur initially -0-% of the time and increase monthly by -0-% to a maximum of -0-%. · The monthly trading volume would average $1,396,213 to $1,417,040 and would increase at 1% per month. · The stock price would fluctuate with the Company projected volatility using a random sampling (450,000 iterations for each valuation) from a normal distribution. The stock price of the underlying instrument is modelled such that it follows a geometric Brownian motion with constant drift and volatility. · The Holder would exercise the warrants after one trading day as they become exercisable (at issuance) at target prices of 3 to 5 times the projected reset price or higher. · Reset events were projected to occur by 12/31/17 and 12/31/18 – the reset provision ends 3/30/19 and the option expires 3/30/20. · The stock price would fluctuate with an annual volatility. The projected annual volatility curve for each valuation period was based on the historical annual volatility of the company and the term remaining in the range 258% - 257%. · The Holder would exercise the warrant at maturity in 2020 if the stock price was above the reset exercise price.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Note 12 - Commitments and Contingencies	Collaborative Patent License Agreements On May 9, 2012, the Company entered into a Collaborative Agreement with the University of Texas at El Paso. Pursuant to the terms of the Agreement, the Company will work jointly with the University to develop a series of research and development programs around its sequential-dialysis technology in the areas of Alzheimer’s Disease, Traumatic Brain Injury (TBI), Chronic Pain Syndrome, Fibromyalgia, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease), Blood Sepsis, Cancer, Heart Attacks and Strokes. The programs will utilize the facilities at one or more of the University of Texas’ campuses. The Company will pay the University’s actual overhead for the projects, plus a negotiated facility and administration overhead expense, and 10% of all gross revenues associated with the sale, license and/or royalties of all products and treatment procedures directly affiliated with programs. Intellectual property jointly invented and developed as a result of the projects will be owned jointly by the University and the Company. The Agreement has an initial term of five (5) years, and is renewable upon mutual agreement of the parties. On March 4, 2015, we entered into a Patent License Agreement (PLA) with the University of Texas at El Paso (UTEP) regarding our joint research and development of CTLA-4 Blockade with Metronomic Chemotherapy for the Treatment of Breast Cancer. This is the first PLA with UTEP following our Collaborative Agreement with them dated May 9, 2012, and memorializes the joint ownership of the applicable patent and the financial and other terms related thereto. On June 19, 2015, we entered into Amendment No. 1 to this Agreement, pursuant to which we explicitly included Provisional Patent Application No. 62/161,116 entitled, “Anti-CTLA-4 Blockade” (the “Application”) under the definition of “Patent Rights” as set forth in the PLA. The Application was filed with the United States Patent and Trademarks Office on May 13, 2015; the underlying technology was invented by Robert Kirken and Georgialina Rodriguez, and is solely-owned by The Board of Regents of The University of Texas System. On October 31, 2017 we entered into an Agreement, Final Payment under Contract, and Release of all Claims, whereby we agreed to pay them a total of $326,336 arising out of the research and development agreements with an initial payment of $22,211, and monthly payments of varying amounts between $5,000 and $20,000 thereafter for twenty eight months until the balance is paid in full. Subject to the compliance of all terms, the intellectual property rights established and arising out of the collaborative agreements remain in full force and effect and the parties agreed to a mutual release upon the final contracted payment. The full amount of the liability has been recognized as an accounts payable as of the date of this filing.

Changes in Stockholders_ Equity

Changes in Stockholders’ Equity (Deficit)	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Note 13 - Changes in Stockholders’ Equity (Deficit)	Convertible Preferred Stock, Series A The Company has 10,000,000 authorized shares of Preferred Stock, of which 2,000,000 shares of $0.001 par value Series A Convertible Preferred Stock (“Series A Preferred Stock”) have been designated. Each share of Series A Preferred Stock is convertible, at the option of the holder thereof, at any time after the issuance of such share into one (1) fully paid and non-assessable share of Common Stock. Each outstanding share of Series A Preferred Stock is entitled to one hundred (100) votes per share on all matters to which the shareholders of the Corporation are entitled or required to vote. The Company shall reserve and keep available out of its authorized but unissued shares of Common Stock such number of shares sufficient to effect the conversions. Common Stock The Company has one billion authorized shares of $0.00001 par value Common Stock, as increased pursuant to an amendment to the articles of incorporation on February 9, 2016. Securities Purchase Agreement On March 30, 2017, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) by and between the Company and each of The Special Equities Group, LLC, RDW Capital LLC, and DiamondRock, LLC (each a “Purchaser” and collectively, the “Purchasers”) to sell our common stock and warrants at a fixed price. Pursuant to the Purchase Agreement, we received from the Purchasers an aggregate of $300,000, net of $15,000 of offering costs, in exchange for 40,000,002 shares of our common stock, warrants to purchase up to 40,000,002 shares of our common stock at an exercise price of $0.03 (“Series A Warrants”) and warrants to purchase up to 40,000,002 shares or our common stock at an exercise price of $0.05 (“Series B Warrants”). Both the Series A Warrants and Series B Warrants issued pursuant to the Purchase Agreement are exercisable immediately upon receipt and have a term of three years. In addition, the Purchaser is entitled to a one-time price reset on the purchase price of the common stock of each tranche to the lower of (i) $0.02 or (ii) a 50% discount to the average of the three lowest closing prices in the 20 trading days prior to the reset date, which is the earlier of (i) the 7 month anniversary of the closing of each tranche of this transaction or (ii) 20 trading days after the effectiveness of each tranche. The embedded value in this reset provision is disclosed further in Note 10. On May 30, 2017, the Purchasers bought additional shares of our common stock and warrants for $150,000 (the “Second Closing”), in exchange for 30,303,033 shares of our common stock, warrants to purchase up to 30,303,033 shares of our common stock at an exercise price of $0.03 (“Series A Warrants”) and warrants to purchase up to 30,303,033 shares or our common stock at an exercise price of $0.05 (“Series B Warrants”). Both the Series A Warrants and Series B Warrants issued pursuant to the Purchase Agreement are exercisable immediately upon receipt and have a term of three years. The per share purchase price of the Second Closing was the lesser of (i) $0.02, subject to certain adjustments for stock splits and other similar transactions, or (ii) 50% of the closing price on the trading day immediately prior to the date of sale. The total number of shares to be sold in the Second Closing were determined by dividing the total purchase amount of each closing (i.e., $150,000) by the per share purchase price. The Purchase Agreement limits each Purchaser to beneficial ownership of our common stock of no more than 9.99%. The Purchasers also have certain anti-dilution rights in the Purchase Agreement for a period of 12 months. These rights allow the Purchasers to exchange their shares of common stock received pursuant to the Purchase Agreement for additional shares on the same terms and conditions of a subsequent financing. On August 8, 2017, the Company and each of the three Purchasers also entered into exchange agreements whereby the Purchasers exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (aggregate $150,000) issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. Registration Rights Agreement On March 30, 2017, we entered into a Registration Rights Agreement with the Purchasers in connection with the Purchase Agreement. In the Registration Rights Agreement, we agreed to prepare and file a registration statement with the Securities and Exchange Commission covering the resale of all of the shares of common stock sold to the Purchasers and the shares issuable upon exercise of the Series A Warrants and Series B Warrants. We agreed to file an initial registration statement as promptly as possible and have it declared effective no later than June 28, 2017 (or July 28, 2017 if the registration statement was reviewed by the Securities and Exchange Commission) and keep it continuously effective until the securities are sold or may be sold under Rule 144 of the Securities Act without volume or manner-of-sale restrictions. If all of the securities cannot be registered on one registration statement, we agreed to file subsequent registration statements to register the remaining securities as promptly as allowed. The registration statement was subsequently withdrawn on July 24, 2017 and the Purchase Agreement was amended on August 8, 2017 to change the terms of the third closing to an aggregate of $150,000 of convertible notes, bearing interest at 8%, convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. Common Stock Issuances for Debt Conversions On various dates between January 10, 2017 and March 13, 2017, the Company issued a total of 142,148,242 shares of common stock pursuant to the conversion of an aggregate of $323,197, consisting of $302,480 of principal and $20,717 of interest, among the Second, Fifth and Seventh Redwood Notes. The notes were converted in accordance with the conversion terms; therefore no gain or loss has been recognized. Common Stock Issuances on Stock Purchase Agreement On February 13, 2017, the Company drew down $8,000 on their Stock Purchase Agreement entered into on May 27, 2016, with Redwood and issued 2,000,000 shares of common stock pursuant to the Seventh Put Notice. On January 10, 2017, the Company drew down $10,323 on their Stock Purchase Agreement entered into on May 27, 2016, with Redwood and issued 3,147,110 shares of common stock pursuant to the Sixth Put Notice.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Note 14 - Income Taxes	The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. For the nine months ended September 30, 2017, and the year ended December 31, 2016, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At September 30, 2017, and December 31, 2016, the Company had approximately $4,917,000 and $4,334,000 of federal net operating losses, respectively. The net operating loss carry forwards, if not utilized, will begin to expire in 2031. The components of the Company’s deferred tax asset are as follows: September 30, December 31, 2017 2016 Deferred tax assets: Net operating loss carry forwards $ 1,720,950 $ 1,516,900 Net deferred tax assets before valuation allowance $ 1,720,950 $ 1,516,900 Less: Valuation allowance (1,720,950 ) (1,516,900 ) Net deferred tax assets $ - $ - Based on the available objective evidence, including the Company’s history of losses, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at September 30, 2017, and December 31, 2016, respectively. A reconciliation between the amounts of income tax benefit determined by applying the applicable U.S. and state statutory income tax rate to pre-tax loss is as follows: September 30, December 31, 2017 2016 Federal and state statutory rate 35 % 35 % Change in valuation allowance on deferred tax assets (35 %) (35 %) In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Note 15 - Subsequent Events	Common Stock Issuances for Debt Conversions On various dates between October 31, 2017 and November 17, 2017, the Company issued a total of 39,336,623 shares of common stock pursuant to the conversion of an aggregate of $75,000 of principal, among the First RDW, SEG and Diamond Rock Notes. The notes were converted in accordance with the conversion terms; therefore no gain or loss has been recognized.

Basis of Presentation and Sig21

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2017
Basis Of Presentation And Significant Accounting Policies Policies
Basis of Presentation	The accompanying unaudited, condensed financial statements of Premier Biomedical, Inc. (“the Company”) have been prepared pursuant to rules and regulations of the Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, these statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. It is suggested that these statements be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.
Equity Method	Investee companies that are not consolidated, but over which the Company exercises significant influence, are accounted for under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an Investee depends on an evaluation of several factors including, among others, representation on the Investee company’s board of directors and ownership level, which is generally a 20% to 50% interest in the voting securities of the Investee company. Under the equity method of accounting, an Investee company’s accounts are not reflected within the Company’s Balance Sheets and Statements of Operations; however, the Company’s share of the earnings or losses of the Investee company is reflected in the caption “Equity in losses of unconsolidated entity” in the Statements of Operations. The Company’s carrying value in an equity method Investee company is typically reflected in the caption “Investment in Joint Venture.” in the Company’s Balance Sheets. As of September 30, 2017, our share of losses from the investee company exceeded our basis, therefore the investment is not currently presented on the balance sheet. U.S. GAAP considers a change in reporting entity to include “changing specific subsidiaries that make up the group of entities for which consolidated financial statements are presented.” Circumstances may arise where a parent’s controlling financial interest (e.g., generally an ownership interest in excess of 50 percent of the outstanding voting stock) is reduced to a noncontrolling investment that still enables it to exercise significant influence over the operating and financial policies of the investee. A change that results from changed facts and circumstances (such as a partial sale of a subsidiary), where there was only one acceptable method of accounting prior to the change in circumstances (consolidation) and only one acceptable method of accounting after the change (equity method accounting), is not a change in reporting entity and is not be accounted for retrospectively. Accordingly, a change from a controlling interest to a noncontrolling investment accounted for under the equity method is accounted for prospectively from the date of change in control. When the Company’s carrying value in an equity method Investee company is reduced to zero, no further losses are recorded in the Company’s consolidated financial statements unless the Company guaranteed obligations of the Investee company or has committed additional funding. When the Investee company subsequently reports income, the Company will not record its share of such income until it equals the amount of its share of losses not previously recognized.
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	We maintain cash balances in non-interest-bearing accounts, which do not currently exceed federally insured limits. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents.
Patent Rights and Applications	Patent rights and applications costs include the acquisition costs and costs incurred for the filing of patents. Patent rights and applications are amortized on a straight-line basis over the legal life of the patent rights beginning at the time the patents are approved. Patent costs for unsuccessful patent applications are expensed when the application is terminated.
Fair Value of Financial Instruments	Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, prepaid expenses and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short term nature of the instruments.
Basic and Diluted Loss Per Share	The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.
Stock-Based Compensation	Under FASB ASC 718-10-30-2, all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative. The Company’s stock based compensation consisted of the following during the nine months ended September 30, 2017 and 2016, respectively: September 30, September 30, 2017 2016 Common stock issued for services $ - $ 58,800 Warrants issued for services, related parties - 19,595 Warrants issued for services - 16,032 Total stock based compensation $ - $ 94,427
Revenue Recognition	Sales on fixed price contracts are recorded when services are earned, the earnings process is complete or substantially complete, and the revenue is measurable and collectability is reasonably assured. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue from sales in which payment has been received, but the earnings process has not occurred. Sales commenced on July 5, 2017 with the termination of our joint venture and are recognized upon shipment of goods, which are typically paid for at the time of order.
Advertising and Promotion	All costs associated with advertising and promoting products are expensed as incurred. These expenses were $42,793 and $67,216 for the nine months ended September 30, 2017 and 2016, respectively.
Income Taxes	Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations.
Uncertain Tax Positions	In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.
Recent Accounting Pronouncements	In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2017-09 , Compensation — Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-9 In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other (Topic 350) In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business No other new accounting pronouncements, issued or effective during the nine months ended September 30, 2017, have had or are expected to have a significant impact on the Company’s financial statements.

Basis of Presentation and Sig22

Basis of Presentation and Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2017
Basis Of Presentation And Significant Accounting Policies Tables
Stock-Based Compensation	September 30, September 30, 2017 2016 Common stock issued for services $ - $ 58,800 Warrants issued for services, related parties - 19,595 Warrants issued for services - 16,032 Total stock based compensation $ - $ 94,427

Restatement (Tables)

Restatement (Tables)	9 Months Ended
	Sep. 30, 2017
Restatement Tables
Restated Balance Sheet:	PREMIER BIOMEDICAL, INC. BALANCE SHEET As Originally Reported As Restated September 30, September 30, 2016 Adjustments 2016 ASSETS Current assets: Cash $ 27,821 $ - $ 27,821 Prepaid expenses 13,045 - 13,045 Total current assets 50,133 - 50,133 Property and equipment, net 5,629 - 5,629 Total assets $ 46,495 $ - $ 46,495 LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Current liabilities: Accounts payable $ 210,055 $ - $ 210,055 Accounts payable, related parties 52,244 - 52,244 Accrued interest 43,330 - 43,330 Accrued interest, related parties 2,970 - 2,970 Judgment payable 340,647 - 340,647 Convertible notes payable, net of discounts of $74,287 184,470 (28,837 ) 155,633 Notes payable, related parties 30,000 - 30,000 Derivative liabilities - 184,583 184,583 Total current liabilities 863,716 155,746 1,019,462 Total liabilities 863,716 155,746 1,019,462 Commitments and contingencies - - - Stockholders’ equity (deficit): Preferred stock, $0.001 par value, 10,000,000 shares authorized, 2,000,000 shares issued and outstanding 2,000 - 2,000 Common stock, $0.00001 par value, 1,000,000,000 shares authorized, 185,858,819 shares issued and outstanding 1,859 - 1,859 Additional paid in capital 11,529,099 (124,296 ) 11,404,803 Accumulated deficit (12,350,179 ) (31,450 ) (12,381,629 ) Total stockholders’ equity (deficit) (817,221 ) (155,746 ) (972,967 ) Total liabilities and stockholders’ equity (deficit) $ 46,495 $ - $ 46,495
Restated Statement of Operations	The following adjustments were made to the Nine Months Ended September 30, 2016 Restated Statement of Operations: PREMIER BIOMEDICAL, INC. STATEMENT OF OPERATIONS As Originally Reported As Restated September 30, September 30, 2016 Adjustments 2016 Revenue $ - $ - $ - Operating expenses: Research and development 105,742 - 105,742 General and administrative 128,032 - 128,032 Professional fees 294,496 - 294,496 Total operating expenses 528,270 - 528,270 Net operating loss (528,270 ) - (528,270 ) Other expense: Interest expense (703,465 ) 12,220 (691,245 ) Other expense (340,647 ) - (340,647 ) Change in derivative liabilities - (24,434 ) (24,434 ) Total other expenses (1,044,112 ) (12,214 ) (1,056,326 ) Net loss $ (1,572,382 ) $ (12,214 ) $ (1,584,596 ) The following adjustments were made to the Three Months Ended September 30, 2016 Restated Statement of Operations: PREMIER BIOMEDICAL, INC. STATEMENT OF OPERATIONS As Originally Reported As Restated September 30, September 30, 2016 Adjustments 2016 Revenue $ - $ - $ - Operating expenses: Research and development 46,056 - 46,056 General and administrative 36,566 - 36,566 Professional fees 68,537 - 68,537 Total operating expenses 151,159 - 151,159 Net operating loss (151,159 ) - (151,159 ) Other expense: Interest expense (283,988 ) 1,554 (282,434 ) Change in derivative liabilities - 63,428 - Total other expenses (283,988 ) 64,982 (219,006 ) Net loss $ (435,147 ) $ 64,982 $ (370,165 )
Restated Statement of Cash Flows	PREMIER BIOMEDICAL, INC. STATEMENT OF CASH FLOWS As Originally Reported As Restated September 30, September 30, 2016 Adjustments 2016 CASH FLOWS FROM OPERATING ACTIVITIES Net loss $ (1,572,382 ) $ (12,214 ) $ (1,584,596 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation 1,554 - 1,554 Change in fair market value of derivative liabilities - 24,434 24,434 Amortization of debt discounts 645,365 (12,220 ) 633,145 Stock based compensation, related parties 19,595 - 19,595 Stock based compensation 74,832 - 74,832 Decrease (increase) in assets: Prepaid expenses (3,879 ) - (3,879 ) Increase (decrease) in liabilities: Accounts payable 21,790 - 21,790 Accounts payable, related parties 11,341 - 11,341 Accrued interest 56,299 - 56,299 Accrued interest, related parties 1,800 - 1,800 Judgment payable 340,647 - 340,647 Net cash used in operating activities (403,038 ) - (403,038 ) CASH FLOWS FROM INVESTING ACTIVITIES Purchases of property and equipment (3,536 ) - (3,536 ) Net cash used in investing activities (3,536 ) - (3,536 ) CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from exercise of warrants, related party 2,000 - 2,000 Proceeds from sale of stock on equity line of credit 68,520 - 68,520 Proceeds from convertible notes payable 417,500 - 417,500 Repayments from convertible notes payable (89,039 ) - (89,039 ) Net cash provided by financing activities 398,981 - 398,981 NET CHANGE IN CASH (7,593 ) - (7,593 ) CASH AT BEGINNING OF PERIOD 35,414 - 35,414 CASH AT END OF PERIOD $ 27,821 $ - $ 27,821 SUPPLEMENTAL INFORMATION: Interest paid $ 13,539 $ - $ 13,539 Income taxes paid $ - $ - $ - NON-CASH INVESTING AND FINANCING ACTIVITIES: Discount on beneficial conversion feature on convertible note $ 364,220 $ (364,220 ) $ - Value of debt discounts $ - $ 369,924 $ 369,924 Value of shares issued for conversion of debt $ 488,552 $ - $ 488,552 Cashless exercise of common stock warrants $ 22 $ - $ 22 Common stock issued for settlement of accounts payable $ 13,765 $ - $ 13,765

Fair Value of Financial Instr24

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2017
Fair Value Of Financial Instruments Tables
Fair Value of Financial Instruments	Fair Value Measurements at September 30, 2017 Level 1 Level 2 Level 3 Assets Cash $ 102,517 $ - $ - Total assets 102,517 - - Liabilities Convertible notes payable 69,150 Notes payable, related parties - 30,000 - Derivative liabilities - - 2,376,295 Total liabilities - 99,150 2,376,295 $ 102,517 $ (99,150 ) $ (2,376,295 ) Fair Value Measurements at December 31, 2016 Level 1 Level 2 Level 3 Assets Cash $ 22,437 $ - $ - Total assets 22,437 - - Liabilities Convertible note payable, net of discounts - 153,024 - Notes payable, related parties 30,000 - Derivative liabilities - - 221,822 Total liabilities - 183,024 221,822 $ 22,437 $ (183,024 ) $ (221,822 )

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2017
Convertible Notes Payable Tables
Summary of convertible note payable	September 30, December 31, 2017 2016 On August 8, 2017, the Company entered into an exchange agreement with Diamond Rock, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First Diamond Rock Note”)issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. $ 50,000 $ - On August 8, 2017, the Company entered into an exchange agreement with The Special Equities Group, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First SEG Note”)issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. 50,000 - On August 8, 2017, the Company entered into an exchange agreement with RDW Capital, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First RDW Note”)issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. 50,000 - On October 10, 2016, the Company issued a 10% interest bearing; unsecured convertible promissory note with a face value of $300,000 (“Seventh Redwood Note”), which matures on October 10, 2017, pursuant to a Warrant Purchase Agreement by and among Redwood Management, LLC, the Company and Typenex. Pursuant to this agreement, Redwood purchased the warrants from Typenex, and Typenex provided a Satisfaction of Judgment and Release of Garnishment to release the Writ of Garnishment Typenex had placed on our transfer agent. Redwood paid installment payments to Typenex in the aggregate amount of $300,000, which were completed on, or about November 10, 2016. The principal and interest of the Seventh Redwood Note is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law. This settled the dispute with Typenex. A total of $308,750, consisting of $300,000 of principal and $8,750 of interest, was converted into 135,596,882 shares of common stock on various dates between November 21, 2016 and February 24, 2017. $ - $ 275,000 On March 11, 2016, the Company received net proceeds of $90,000 in exchange for a 10% interest bearing; unsecured convertible promissory note with a face value of $105,000 (“Fifth Redwood Note”), which matures on December 11, 2016. The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law. A total of $120,517, consisting of $105,000 of principal and $15,517 of interest, was converted into an aggregate of 47,820,025 shares of common stock at various dates between November 8, 2016 and March 13, 2017. - 27,480 Total convertible notes payable 150,000 302,480 Less unamortized derivative discounts: 80,850 149,456 Convertible notes payable 69,150 153,024 Less: current portion 69,150 153,024 Convertible notes payable, less current portion $ - $ -
Recognized interest expense	September 30, September 30, 2017 2016 Interest on convertible notes $ 4,434 $ 35,048 Interest on related party loans 1,800 1,200 Amortization of beneficial conversion feature - 81,648 Amortization of OID - 20,647 Amortization of loan origination costs - 44,811 Derivative discounts 184,237 225,457 Total interest expense $ 190,471 $ 408,811

Notes Payable, Related Parties

Notes Payable, Related Parties (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Payable Related Parties Tables
Notes payable, related parties	September 30, December 31, 2017 2016 On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from the Company’s CEO. $ 10,000 $ 10,000 On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from the Company’s Chairman of the Board. 10,000 10,000 On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from one of the Company’s Directors. 10,000 10,000 Total notes payable, related parties 30,000 30,000 Less: current portion 30,000 30,000 Notes payable, related parties, less current portion $ - $ -

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	9 Months Ended
	Sep. 30, 2017
Derivative Liabilities Tables
Summary of Changes in fair market value Derivative Liability	Derivative Liability Total Balance, December 31, 2015 $ 150,076 Increase in derivative value due to issuances of convertible promissory notes 583,415 Change in fair market value of derivative liabilities due to the mark to market adjustment 13,816 Debt conversions (525,485 ) Balance, December 31, 2016 $ 221,822 Increase in derivative value due to issuances of convertible promissory notes 115,631 Increase in derivative value due to issuances of warrants 3,337,007 Change in fair market value of derivative liabilities due to the mark to market adjustment (1,069,122 ) Debt conversions (229,043 ) Balance, September 30, 2017 $ 2,376,295

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2017
Income Taxes Tables
Deferred tax asset	September 30, December 31, 2017 2016 Deferred tax assets: Net operating loss carry forwards $ 1,720,950 $ 1,516,900 Net deferred tax assets before valuation allowance $ 1,720,950 $ 1,516,900 Less: Valuation allowance (1,720,950 ) (1,516,900 ) Net deferred tax assets $ - $ -
Reconciliation between the amounts of income tax	September 30, December 31, 2017 2016 Federal and state statutory rate 35 % 35 % Change in valuation allowance on deferred tax assets (35 %) (35 %)

Basis of Presentation and Sig29

Basis of Presentation and Significant Accounting Policies (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Basis Of Presentation And Significant Accounting Policies Details
Common stock issued for services		$ 58,800
Warrants issued for services, related parties		19,595
Warrants issued for services		16,032
Total stock based compensation		$ 94,427

Basis of Presentation and Sig30

Basis of Presentation and Significant Accounting Policies (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Advertising and promotion expenses	$ 42,793	$ 67,216
Minimum [Member]
Ownership interest	20.00%
Maximum [Member]
Ownership interest	50.00%

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Going Concern Details Narrative
Accumulated deficit	$ (15,420,260)	$ (12,565,254)
Working capital deficit	$ (2,666,087)

Restatement (Details)

Restatement (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016
Current assets:
Cash	$ 102,517	$ 22,437
Prepaid Expenses	7,435	11,430
Total current assets	218,792	33,867
Property and equipment, net	5,940	5,100
Total assets	224,732	38,967
Current liabilities:
Accounts Payable	350,077	220,740
Accounts payable, related parties	52,244	52,489
Accrued interest	1,743	18,026
Accrued interest, related parties	5,370	3,570
Convertible notes payable, net of discounts of $74,287	69,150	153,024
Notes payable, related parties	30,000	30,000
Derivative liabilities	2,376,295	221,822
Total current liabilities	2,884,879	699,671
Total liabilities	2,884,879	699,671
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, $0.001 par value, 10,000,000 sharesauthorized, 2,000,000 shares issued and outstanding	2,000	2,000
Common stock, $0.00001 par value, 1,000,000,000 shares authorized, 185,858,819 shares issued and outstanding	4,919	3,046
Additional paid in capital	12,753,194	11,899,504
Accumulated deficit	(15,420,260)	(12,565,254)
Total stockholders' equity (deficit)	(2,660,147)	(660,704)
Total liabilities and stockholders' equity (deficit)	$ 224,732	$ 38,967
As Originally Reported [Member]
Current assets:
Cash			$ 27,821
Prepaid Expenses			13,045
Total current assets			50,133
Property and equipment, net			5,629
Total assets			46,495
Current liabilities:
Accounts Payable			210,055
Accounts payable, related parties			52,244
Accrued interest			43,330
Accrued interest, related parties			2,970
Judgment payable			340,647
Convertible notes payable, net of discounts of $74,287			184,470
Notes payable, related parties			30,000
Derivative liabilities
Total current liabilities			863,716
Total liabilities			863,716
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, $0.001 par value, 10,000,000 sharesauthorized, 2,000,000 shares issued and outstanding			2,000
Common stock, $0.00001 par value, 1,000,000,000 shares authorized, 185,858,819 shares issued and outstanding			1,859
Additional paid in capital			11,529,099
Accumulated deficit			(12,350,179)
Total stockholders' equity (deficit)			(817,221)
Total liabilities and stockholders' equity (deficit)			46,495
Adjustment [Member]
Current assets:
Cash
Prepaid Expenses
Total current assets
Property and equipment, net
Total assets
Current liabilities:
Accounts Payable
Accounts payable, related parties
Accrued interest
Accrued interest, related parties
Judgment payable
Convertible notes payable, net of discounts of $74,287			(28,837)
Notes payable, related parties
Derivative liabilities			184,583
Total current liabilities			155,746
Total liabilities			155,746
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, $0.001 par value, 10,000,000 sharesauthorized, 2,000,000 shares issued and outstanding
Common stock, $0.00001 par value, 1,000,000,000 shares authorized, 185,858,819 shares issued and outstanding
Additional paid in capital			(124,296)
Accumulated deficit			(31,450)
Total stockholders' equity (deficit)			(155,746)
Total liabilities and stockholders' equity (deficit)
As Restated [Member]
Current assets:
Cash			27,821
Prepaid Expenses			13,045
Total current assets			50,133
Property and equipment, net			5,629
Total assets			46,495
Current liabilities:
Accounts Payable			210,055
Accounts payable, related parties			52,244
Accrued interest			43,330
Accrued interest, related parties			2,970
Judgment payable			340,647
Convertible notes payable, net of discounts of $74,287			155,633
Notes payable, related parties			30,000
Derivative liabilities			184,583
Total current liabilities			1,019,462
Total liabilities			1,019,462
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, $0.001 par value, 10,000,000 sharesauthorized, 2,000,000 shares issued and outstanding			2,000
Common stock, $0.00001 par value, 1,000,000,000 shares authorized, 185,858,819 shares issued and outstanding			1,859
Additional paid in capital			11,404,803
Accumulated deficit			(12,381,629)
Total stockholders' equity (deficit)			(972,967)
Total liabilities and stockholders' equity (deficit)			$ 46,495

Restatement (Details 1)

Restatement (Details 1) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue	$ 24,276		$ 24,276
Operating expenses:
Research and development	184,315		184,315
General and administrative	36,979		110,284
Professional fees	22,269		109,025
Total operating expenses	243,563		403,624
Net operating loss	(230,357)		(390,418)
Other expense:
Interest expense	(37,124)		(190,471)
Change in derivative liabilities	(3,993,216)		2,267,885	$ 24,434
Total other expenses	3,951,918		(2,464,588)
Net loss	$ 3,721,561		$ (2,855,006)
As Originally Reported [Member]
Revenue
Operating expenses:
Research and development		46,056		105,742
General and administrative		36,566		128,032
Professional fees		68,537		294,496
Total operating expenses		151,159		528,270
Net operating loss		(151,159)		(528,270)
Other expense:
Interest expense		(283,988)		(703,465)
Other expense				(340,647)
Change in derivative liabilities
Total other expenses		(283,988)		(1,044,112)
Net loss		(435,147)		(1,572,382)
Adjustment [Member]
Revenue
Operating expenses:
Research and development
General and administrative
Professional fees
Total operating expenses
Net operating loss
Other expense:
Interest expense		1,554		12,220
Other expense
Change in derivative liabilities		63,428		(24,434)
Total other expenses		64,982		(12,214)
Net loss		64,982		(12,214)
As Restated [Member]
Revenue
Operating expenses:
Research and development		46,056		105,742
General and administrative		36,566		128,032
Professional fees		68,537		294,496
Total operating expenses		151,159		528,270
Net operating loss		(151,159)		(528,270)
Other expense:
Interest expense		(282,434)		(691,245)
Other expense				(340,647)
Change in derivative liabilities				(24,434)
Total other expenses		(219,006)		(1,056,326)
Net loss		$ (370,165)		$ (1,584,596)

Restatement (Details 2)

Restatement (Details 2) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ 3,721,561		$ (2,855,006)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation			1,854
Change in fair market value of derivative liabilities	3,993,216		(2,267,885)	$ (24,434)
Amortization of debt discount			184,237
Stock based compensation, related parties
Stock based compensation
Decrease (increase) in assets:
Prepaid expenses			(3,995)
Increase (decrease) in liabilities:
Accounts payable			129,337
Accounts payable, related parties			(245)
Accrued interest			4,434
Accrued interest, related parties			(1,800)	(1,200)
Judgment payable
Net cash used in operating activities			(370,549)
CASH FLOWS FROM INVESTING ACTIVITIES
Net cash used in investing activities			(2,694)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of warrants, related party
Proceeds from sale of stock on equity line of credit			18,323
Proceeds from convertible notes payable			150,000
Repayments from convertible notes payable
Net cash provided by financing activities			453,323
NET CHANGE IN CASH			80,080
CASH AT BEGINNING OF PERIOD			22,437
CASH AT END OF PERIOD	$ 102,517		102,517
SUPPLEMENTAL INFORMATION:
Interest paid
Income taxes paid
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Value of debt discounts			115,631
Value of shares issued for conversion of debt			323,197
Cashless exercise of common stock warrants
Common stock issued for settlement of accounts payable
As Originally Reported [Member]
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		$ (435,147)		(1,572,382)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation				1,554
Change in fair market value of derivative liabilities
Amortization of debt discount				645,365
Stock based compensation, related parties				19,595
Stock based compensation				74,832
Decrease (increase) in assets:
Prepaid expenses				(3,879)
Increase (decrease) in liabilities:
Accounts payable				21,790
Accounts payable, related parties				11,341
Accrued interest				56,299
Accrued interest, related parties				1,800
Judgment payable				340,647
Net cash used in operating activities				(403,038)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment				(3,536)
Net cash used in investing activities				(3,536)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of warrants, related party				2,000
Proceeds from sale of stock on equity line of credit				68,520
Proceeds from convertible notes payable				417,500
Repayments from convertible notes payable				(89,039)
Net cash provided by financing activities				398,981
NET CHANGE IN CASH				(7,593)
CASH AT BEGINNING OF PERIOD				35,414
CASH AT END OF PERIOD		27,821		27,821
SUPPLEMENTAL INFORMATION:
Interest paid				13,539
Income taxes paid
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Discount on beneficial conversion feature on convertible note				364,220
Value of debt discounts
Value of shares issued for conversion of debt				488,552
Cashless exercise of common stock warrants				22
Common stock issued for settlement of accounts payable				13,765
Adjustment [Member]
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		64,982		(12,214)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Change in fair market value of derivative liabilities		(63,428)		24,434
Amortization of debt discount				(12,220)
Stock based compensation, related parties
Stock based compensation
Decrease (increase) in assets:
Prepaid expenses
Increase (decrease) in liabilities:
Accounts payable
Accounts payable, related parties
Accrued interest
Accrued interest, related parties
Judgment payable
Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of warrants, related party
Proceeds from sale of stock on equity line of credit
Proceeds from convertible notes payable
Repayments from convertible notes payable
Net cash provided by financing activities
NET CHANGE IN CASH
CASH AT BEGINNING OF PERIOD
CASH AT END OF PERIOD
SUPPLEMENTAL INFORMATION:
Interest paid
Income taxes paid
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Discount on beneficial conversion feature on convertible note				(364,220)
Value of debt discounts				369,924
Value of shares issued for conversion of debt
Cashless exercise of common stock warrants
Common stock issued for settlement of accounts payable
As Restated [Member]
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		(370,165)		(1,584,596)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation				1,554
Change in fair market value of derivative liabilities				24,434
Amortization of debt discount				633,145
Stock based compensation, related parties				19,595
Stock based compensation				74,832
Decrease (increase) in assets:
Prepaid expenses				(3,879)
Increase (decrease) in liabilities:
Accounts payable				21,790
Accounts payable, related parties				11,341
Accrued interest				56,299
Accrued interest, related parties				1,800
Judgment payable				340,647
Net cash used in operating activities				(403,038)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment				(3,536)
Net cash used in investing activities				(3,536)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of warrants, related party				2,000
Proceeds from sale of stock on equity line of credit				68,520
Proceeds from convertible notes payable				417,500
Repayments from convertible notes payable				(89,039)
Net cash provided by financing activities				398,981
NET CHANGE IN CASH				(7,593)
CASH AT BEGINNING OF PERIOD				35,414
CASH AT END OF PERIOD		$ 27,821		27,821
SUPPLEMENTAL INFORMATION:
Interest paid				13,539
Income taxes paid
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Discount on beneficial conversion feature on convertible note
Value of debt discounts				369,924
Value of shares issued for conversion of debt				488,552
Cashless exercise of common stock warrants				22
Common stock issued for settlement of accounts payable				$ 13,765

Related Parties (Details Narrat

Related Parties (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Sep. 30, 2017	Dec. 31, 2016	Jul. 06, 2015
Accrued interest, related parties	$ 5,370	$ 5,370	$ 3,570
Equity in losses of investment in joint venture	(4,174)	(6,232)
Board of Directors Chairman [Member]
Amount owed	46,016	46,016	46,016
Reimbursable expenses		5,623	6,167
Unsecured loan				$ 10,000
Interest rate				8.00%
Director [Member]
Unsecured loan				$ 10,000
Interest rate				8.00%
Chief Executive Officer [Member]
Reimbursable expenses		605	$ 306
Unsecured loan				$ 10,000
Interest rate				8.00%
Joint Venture Partner [Member]
Other receivable, related party	48,778	48,778
Other receivable, Amount	44,604	44,604
Amount of original investment		2,058
Loss on other receivable		4,174
Equity in losses of investment in joint venture		(6,232)
Notes Payable, Related Parties [Member]
Accrued interest, related parties	$ 5,370	$ 5,370
Notes Payable, Related Parties [Member] | Board of Directors Chairman [Member]
Unsecured loan				$ 10,000
Notes Payable, Related Parties [Member] | Director [Member]
Unsecured loan				10,000
Notes Payable, Related Parties [Member] | Chief Executive Officer [Member]
Unsecured loan				$ 10,000

Fair Value of Financial Instr36

Fair Value of Financial Instruments (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Assets
Cash	$ 102,517	$ 22,437
Liabilities
Convertible note payable, net of discounts	69,150	153,024
Notes payable, related parties
Derivative liabilities	2,376,295	221,822	$ 150,076
Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Assets
Cash	102,517	22,437
Total assets	102,517	22,437
Liabilities
Convertible note payable, net of discounts
Notes payable, related parties
Derivative liabilities
Total liabilities
Net assets and liabilities	102,517	22,437
Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Assets
Cash
Total assets
Liabilities
Convertible note payable, net of discounts	69,150	153,024
Notes payable, related parties	30,000	30,000
Derivative liabilities
Total liabilities	99,150	183,024
Net assets and liabilities	(99,150)	(183,024)
Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Assets
Cash
Total assets
Liabilities
Convertible note payable, net of discounts
Notes payable, related parties
Derivative liabilities	2,376,295	221,822
Total liabilities	2,376,295	221,822
Net assets and liabilities	$ (2,376,295)	$ (221,822)

Joint Venture (Details Narrativ

Joint Venture (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2017	Sep. 13, 2016
Common stock warrants	1,250,000	1,250,000
Strike price		$ 0.05
Capital contribution		$ 25,000
Capital description		ATS will contribute (i) technical, labor, manufacturing information and know-how required to produce the initial product, an extended duration topical pain relief patch; (ii) $5,000 worth of primary ingredients; and (iii) $5,000 worth of other materials to produce the initial prototype pain relief patches.
Equity in losses of investment in joint venture	$ (4,174)	$ (6,232)
Premier [Member]
Percentage of ownership in PBPMS			50.00%
Percentage of profit allocated from PBPMS			89.00%
ATS [Member]
Percentage of ownership in PBPMS			50.00%
Percentage of profit allocated from PBPMS			11.00%

Convertible Notes Payable (Deta

Convertible Notes Payable (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Total convertible note payable	$ 150,000	$ 302,480
Less unamortized debt derivative discounts	80,850	149,456
Convertible note payable	69,150	153,024
Less: current portion	69,150	153,024
Convertible note payable, less current portion
On August 8 2017 Diamond Rock LLC[Member]
Total convertible note payable	50,000
On August 8 2017 Special Equities Group LLC [Member]
Total convertible note payable	50,000
On August 8 2017 RDW Capital LLC [Member]
Total convertible note payable	50,000
On October 10, 2016 Unserured loan [Member]
Total convertible note payable		275,000
On March 11, 2016 Unsecured loan [Member]
Total convertible note payable		$ 27,480

Convertible Notes Payable (De39

Convertible Notes Payable (Details 1) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Convertible Notes Payable Details 1
Interest on convertible notes	$ 4,434	$ 35,048
Interest on related party loans	1,800	1,200
Amortization of beneficial conversion feature		81,648
Amortization of OID		20,647
Amortization of loan origination costs		44,811
Derivative discounts	184,237	225,457
Total interest expense	$ 190,471	$ 408,811

Convertible Notes Payable (De40

Convertible Notes Payable (Details Narrative) - USD ($)	Aug. 08, 2017	Oct. 10, 2016	Mar. 11, 2016
November 21, 2016 and February 24, 2017 [Member] | Typenex [Member]
Converted shares		135,596,882
Converted amount		$ 300,000
Interest expense		8,750
Total		$ 308,750
RDW Capital LLC [Member]
Common stock shares purchased	10,101,011
Interest rate	8.00%
Maturity date	Nov. 30, 2017
Debt description	The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date.
Converted amount	$ 50,000
RDW Capital LLC [Member] | Series A [Member]
Warrant to purchase shares	13,333,334
RDW Capital LLC [Member] | Series B [Member]
Warrant to purchase shares	13,333,334
Special Equities Group LLC [Member]
Common stock shares purchased	10,101,011
Interest rate	8.00%
Maturity date	Nov. 30, 2017
Debt description	The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date.
Converted amount	$ 50,000
Special Equities Group LLC [Member] | Series A [Member]
Warrant to purchase shares	13,333,334
Special Equities Group LLC [Member] | Series B [Member]
Warrant to purchase shares	13,333,334
Diamond Rock LLC [Member]
Common stock shares purchased	10,101,011
Interest rate	8.00%
Maturity date	Nov. 30, 2017
Debt description	The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date.
Converted amount	$ 50,000
Diamond Rock LLC [Member] | Series A [Member]
Warrant to purchase shares	13,333,334
Diamond Rock LLC [Member] | Series B [Member]
Warrant to purchase shares	13,333,334
Seventh Redwood Note [Member]
Interest rate		10.00%
Face value of unsecured convertible promissory note		$ 300,000
Maturity date		Oct. 10, 2017
Total amount paid		$ 300,000
Debt description		The principal and interest of the Seventh Redwood Note is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law.
Fifth Redwood Note [Member]
Interest rate			10.00%
Face value of unsecured convertible promissory note			$ 105,000
Maturity date			Dec. 11, 2016
Debt description			The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law.
Net proceeds			$ 90,000
Fifth Redwood Note [Member] | November 8, 2016 and December 22, 2016 [Member]
Converted shares			47,820,025
Converted amount			$ 105,000
Interest expense			15,517
Total			$ 120,517

Notes Payable, Related Partie41

Notes Payable, Related Parties (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Total notes payable, related parties	$ 30,000	$ 30,000
Less: current portion	30,000	30,000
Notes payable, related parties, less current portion
Chief Executive Officer [Member]
Total notes payable, related parties	10,000	10,000
Board of Directors Chairman [Member]
Total notes payable, related parties	10,000	10,000
Director [Member]
Total notes payable, related parties	$ 10,000	$ 10,000

Notes Payable, Related Partie42

Notes Payable, Related Parties (Details Narrative) - USD ($)	Jul. 06, 2015	Sep. 30, 2017	Sep. 30, 2016
Directors [Member]
Unsecured loan	$ 10,000
Board of Directors Chairman [Member]
Unsecured loan	10,000
Chief Executive Officer [Member]
Unsecured loan	10,000
Notes Payable, Related Parties [Member]
Interest expense		$ 1,800	$ 1,800
Notes Payable, Related Parties [Member] | Directors [Member]
Unsecured loan	$ 10,000
Interest rate	8.00%
Notes Payable, Related Parties [Member] | Board of Directors Chairman [Member]
Unsecured loan	$ 10,000
Interest rate	8.00%
Notes Payable, Related Parties [Member] | Chief Executive Officer [Member]
Unsecured loan	$ 10,000
Interest rate	8.00%

Derivative Liabilities (Details

Derivative Liabilities (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Derivative Liabilities Details
Beginning Balance	$ 221,822	$ 150,076
Increase in derivative value due to issuances of convertible promissory notes	115,631	583,415
Increase in derivative value due to issuances of warrants	3,337,007
Change in fair market value of derivative liabilities due to the mark to market adjustment	(1,069,122)	13,816
Debt conversions	(229,043)	(525,485)
Ending Balance	$ 2,376,295	$ 221,822

Derivative Liabilities (Detai44

Derivative Liabilities (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Derivative liabilities	$ 2,376,295	$ 2,376,295		$ 221,822
Change in derivative liabilities	$ (3,993,216)	2,267,885	$ 24,434
Change in fair value in excess of convertible notes		(3,337,007)	(125,763)
Change in fair market value of the warrants adjustment		1,052,505	$ 101,329
Change in fair market value on convertible notes adjustment		$ 16,617
Convertible debenture [Member] | Warrant [Membe]
Maturity term		2 years
Warrant maturity date		Mar. 30, 2020
Increase in trading fees (monthly)		1.00%
Default event, Description		An event of default would occur -0-% of the time, increasing 2% per month to a maximum of 20%
Fundamental transaction, Description		A change of control and fundamental transaction would occur initially -0-% of the time and increase monthly by -0-% to a maximum of -0-%
Reset event, Description		Reset events were projected to occur by 12/31/17 and 12/31/18 – the reset provision ends 3/30/19 and the option expires 3/30/20
Redeem notes, Description		The Company would redeem the notes -0-% of the time, increasing 1% per month to a maximum of 5%
Description for change in stock price		The stock price would fluctuate with the Company projected volatility using a random sampling (450,000 iterations for each valuation) from a normal distribution
Exercise price of warrants description		The Holder would exercise the warrants after one trading day as they become exercisable (at issuance) at target prices of 3 to 5 times the projected reset price or higher
Maturity year or warrants		2,020
Minimum [Member] | Convertible debenture [Member] | Warrant [Membe]
Stock price		$ 0.009
Volatility		187.00%
Trading fees (monthly)		$ 1,396,213
Minimum [Member] | Convertible debenture [Member] | Warrant [Membe] | Historical Annual Volatility [Member]
Volatility		257.00%
Maximum [Member] | Convertible debenture [Member] | Warrant [Membe]
Stock price		$ 0.0081
Volatility		199.00%
Trading fees (monthly)		$ 1,417,040
Maximum [Member] | Convertible debenture [Member] | Warrant [Membe] | Historical Annual Volatility [Member]
Volatility		258.00%

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	May 09, 2012	Oct. 31, 2017
Research and Development Agreements [Member]
Contractual obligations, amount payable		$ 326,336
Contractual obligations, initial payment		$ 22,211
Contractual obligations, frequency of periodic payment		Monthly
Contractual obligations, number of installments		28
Research and Development Agreements [Member] | Minimum [Member]
Contractual obligations, periodic payments		$ 5,000
Research and Development Agreements [Member] | Maximum [Member]
Contractual obligations, periodic payments		$ 20,000
Collaborative Patent License Agreements [Member]
Sales revenue gross	10.00%
Agreement term	5 years

Changes in Stockholders Equity

Changes in Stockholders Equity (Deficit) (Details Narrative) - USD ($)	Aug. 08, 2017	Jan. 10, 2017	May 30, 2017	Mar. 30, 2017	Feb. 13, 2017	Mar. 13, 2017	Dec. 31, 2016	Sep. 30, 2017
Preferred stock, par value							$ 0.001	$ 0.001
Preferred stock, authorized shares							10,000,000	10,000,000
Common stock, par value							$ 0.00001	$ 0.00001
Common stock, authorized shares							1,000,000,000	1,000,000,000
Convertible note							$ 153,024	$ 69,150
Series A Preferred Stock [Member]
Preferred stock, par value							$ 0.001
Preferred stock, authorized shares							2,000,000
Series A Preferred Stock voting right							100 votes per share
Redwood Convertible Note
Common stock issued on debt conversions, Amount						$ 323,197
Common stock issued on debt conversions, Shares						142,148,242
Principal amount						$ 302,480
Accured Interest						$ 20,717
Common stock issued on equity line of credit, Amount		$ 10,323			$ 8,000
Common stock issued on equity line of credit, Shares		3,147,110			2,000,000
Securities Purchase Agreement [Member]
Aggregate amount				$ 300,000
Deferred offering costs				$ 15,000
Exchange shares of common stock			30,303,033	40,000,002
Warrant exercisable term			3 years	3 years
Effective reset provision, Description				purchase price of the common stock of each tranche to the lower of (i) $0.02 or (ii) a 50% discount to the average of the three lowest closing prices in the 20 trading days prior to the reset date, which is the earlier of (i) the 7 month anniversary of the closing of each tranche of this transaction or (ii) 20 trading days after the effectiveness of each tranche.
Additional shares of common stock and warrant purchase			$ 150,000
Purchase price per share, Description			Second Closing was the lesser of (i) $0.02, subject to certain adjustments for stock splits and other similar transactions, or (ii) 50% of the closing price on the trading day immediately prior to the date of sale.
Securities Purchase Agreement [Member] | Third Closing [Member]
Trading days of common stock	15 days
Traded price of Common stock	50.00%
Interest rate	8.00%
Aggregate amount	$ 150,000
Securities Purchase Agreement [Member] | Second Closing [Member]
Trading days of common stock	15 days
Maturity date	Nov. 30, 2017
Interest rate	8.00%
Convertible note	$ 50,000
Aggregate amount	$ 150,000
Exchange shares of common stock	10,101,011
Series A Warrants [Member] | Securities Purchase Agreement [Member]
Warrant purchase			30,303,033	40,000,002
Warrant exercise price			$ 0.03	$ 0.03
Series A Warrants [Member] | First Closing [Member] | Securities Purchase Agreement [Member]
Exchange shares of common stock	13,333,334
Series B Warrant [Member] | Securities Purchase Agreement [Member]
Warrant purchase			30,303,033	40,000,002
Warrant exercise price			$ 0.05	$ 0.05
Series B Warrant [Member] | First Closing [Member] | Securities Purchase Agreement [Member]
Exchange shares of common stock	13,333,334

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Deferred tax assets:
Net operating loss carry forwards	$ 1,720,950	$ 1,516,900
Net deferred tax assets before valuation allowance	1,720,950	1,516,900
Less: Valuation allowance	(1,720,950)	(1,516,900)
Net deferred tax assets

Income Taxes (Details 1)

Income Taxes (Details 1)	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Income Taxes Details 1
Federal and state statutory rate	35.00%	35.00%
Change in valuation allowance on deferred tax assets	(35.00%)	(35.00%)

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Income Taxes Details Narrative
Federal net operating losses	$ 4,917,000	$ 4,334,000
Federal net operating losses expire	2,031

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member] - RDW, SEG and Diamond Rock Notes [Member]	1 Months Ended
	Nov. 17, 2017USD ($)shares
Debt conversion converted instrument, shares issued | shares	39,336,623
Debt conversion converted amount | $	$ 75,000